{"id":1009147,"date":"2026-10-12T07:05:40","date_gmt":"2026-10-12T11:05:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-the-publication-of-two-year-independent-study-supporting-benefits-of-micropulse-technology-for-early-to-advanced-glaucoma\/"},"modified":"2026-10-12T07:05:40","modified_gmt":"2026-10-12T11:05:40","slug":"iridex-announces-the-publication-of-two-year-independent-study-supporting-benefits-of-micropulse-technology-for-early-to-advanced-glaucoma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iridex-announces-the-publication-of-two-year-independent-study-supporting-benefits-of-micropulse-technology-for-early-to-advanced-glaucoma\/","title":{"rendered":"Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse\u00ae Technology for Early to Advanced Glaucoma"},"content":{"rendered":"

\nStudy reports sustained IOP reduction and reduced medication burden over 24 months
\n<\/h2>\n
\n

SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the publication of a two-year clinical study demonstrating favorable outcomes with transscleral laser therapy (TLT) using MicroPulse\u00ae<\/sup> Technology (referred to as MicroPulse TLT) in patients with early, moderate, and advanced primary glaucoma.<\/p>\n

\u201cThese two-year results are particularly meaningful because they show sustained IOP reduction and reduced medication burden in patients with early-stage glaucoma, as well as in those with moderate and advanced disease,\u201d said Michele Lanza, MD, lead author of the study. \u201cThe findings suggest that MicroPulse TLT may have a role earlier in the glaucoma treatment continuum than has traditionally been considered.\u201d<\/p>\n

Published in the International Journal of Ophthalmology<\/em>, the retrospective study evaluated 84 eyes of 53 patients with primary open-angle glaucoma (POAG) or primary angle-closure glaucoma (PACG). Led by Dr. Lanza of the Universit\u00e0 della Campania Luigi Vanvitelli in Naples, Italy, the study used the Iridex Cyclo G6\u00ae<\/sup> Laser with the original MicroPulse\u00ae<\/sup> P3 Delivery Device. Patients with prior incisional glaucoma surgery were excluded, while those who had undergone selective laser trabeculoplasty (SLT) more than three years earlier remained eligible for inclusion.<\/p>\n

\u201cWe are encouraged by the sustained outcomes reported in this study and the growing body of clinical evidence supporting MicroPulse TLT,\u201d said Patrick Mercer, President and Chief Executive Officer of Iridex. \u201cThese findings further reinforce our commitment to advancing laser-based treatment options for patients with glaucoma.\u201d<\/p>\n

\n
\n Key Findings at 24 Months<\/u>
\n <\/strong>\n <\/p>\n